Screener
Ardelyx ARDX Business Segments — Selling
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept ardx:SellingExpenseAdjusted.
The source filing: Ardelyx’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437402-26-000044
| (in thousands) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of product sales(2) | 3,689 | 3,245 | 6,564 | 5,585 |
| Other cost of revenue(3) | 2,070 | 9,158 | 4,006 | 19,121 |
| Research and development(4) | 23,195 | 13,251 | 40,781 | 24,586 |
| Selling(4) | 66,949 | 57,952 | 134,344 | 114,752 |
| General and administrative(4) | 22,083 | 16,764 | 45,399 | 34,701 |
| Stock-based compensation | 15,316 | 11,687 | 29,474 | 23,775 |
| Loss from operations | (12,425) | (14,395) | (45,218) | (50,744) |
| Other reconciliation items(5) | (4,296) | (4,684) | (9,108) | (9,479) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ardelyx's business segments — selling?
- Ardelyx (ARDX) reported business segments — selling of $66.95M in Q2 2026.
- What does business segments — selling mean?
- Captures the expenses incurred to market, promote, and distribute the company's pharmaceutical products to healthcare providers and patients. These costs are essential for driving product awareness and market penetration in competitive therapeutic areas. Monitoring this helps assess the efficiency of the company's commercial infrastructure.
Ask your AI about Ardelyx's business segments — selling.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude